	US 12,109,208 B2
	Methods of treating or preventing fibrosis in non-alcoholic fatty liver disease
Rajeshwar Mookerjee, London (GB)
Filed by Rajeshwar Mookerjee, London (GB)
Filed on Sep. 25, 2020, as Appl. No. 17/032,260.
Application 17/032,260 is a continuation of application No. PCT/GB2019/050879, filed on Mar. 27, 2019.
Claims priority of application No. 1804922 (GB), filed on Mar. 27, 2018.
Prior Publication US 2021/0085668 A1, Mar. 25, 2021
Int. Cl. A61K 31/475 (2006.01); A61K 31/4178 (2006.01); A61P 1/16 (2006.01); C12Q 1/6876 (2018.01); G01N 33/50 (2006.01)

CPC A61K 31/475 (2013.01) [A61K 31/4178 (2013.01); A61P 1/16 (2018.01); C12Q 1/6876 (2013.01); G01N 33/5067 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/726 (2013.01)]

10 Claims

1. A method of treating or preventing fibrosis in NAFLD in an individual in need thereof, said method comprising a step of administering to said individual an antagonist of alpha 2a adrenergic receptor (ADRA2a).